THE HUMAN VENTILATORY RESPONSE to isocapnic hypoxia is biphasic; there is an initial abrupt increase in ventilation at the onset of hypoxia [known as the acute hypoxic ventilatory response (AHVR)], which is then followed by a subsequent slower decline in ventilation [known as hypoxic ventilatory depression or decline (HVD)] (7). The AHVR arises as a reflex response to the increase in chemoreceptor discharge from the carotid body, but the origins of HVD remain a matter for debate (14, 17) . One substance that affects the ventilatory response to hypoxia is dopamine, which occurs naturally as a neurotransmitter in the carotid body (15, 20) . In humans, infusion of low-dose dopamine (1-5 µg·kg Ϫ1 · min Ϫ1 ) causes a reduction in the AHVR (1, 2, 5, 19, (24) (25) (26) . Whether dopamine affects the subsequent HVD in humans if a period of isocapnic hypoxia is sustained is controversial. Two studies have found that dopamine reduces the magnitude of HVD (5, 25) , and another found that dopamine does not affect HVD (2) . However, in the former two studies, ventilation would have to have fallen below baseline values if the magnitude of HVD were to have remained unaltered. In humans, administration of domperidone, a peripheral dopamine antagonist, causes an elevation of the AHVR (2, 6, 8, 11, 23) but does not affect the magnitude of the following HVD (2, 8) .
Recently, Tatsumi et al. (21) have reported, in both awake and anesthetized cats, that haloperidol, a dopamine antagonist that crosses the blood-brain barrier, abolishes HVD. They conclude that central dopaminergic pathways are involved in the genesis of HVD. The purpose of the present study was to administer haloperidol to human subjects to see whether a similar abolition of HVD can be obtained.
METHODS

Subjects.
Fifteen healthy adults were studied (aged 19-51 yr, 7 men and 8 women). Their individual characteristics are listed in Table 1 . Three of the subjects did not complete the study because of the side effects of haloperidol. All subjects received written and verbal descriptions of the experiment before they gave their consent. The study was approved by the Central Oxford Research Ethics Committee.
Protocols. Before the experiment, subjects came into the laboratory for familiarization with the procedures. The subjects then returned on two different occasions, separated by at least 1 wk, for the actual study. On one day a single dose of haloperidol (Seranace, 0.05 mg/kg) was administered; on the other day a placebo tablet was given. The order of the two experiments was chosen randomly. To evaluate the effects of the drug on ventilation during isocapnic hypoxia, the following hypoxic exposure was employed: end-tidal PO 2 (PET O 2 ) was held at 100 Torr for the first 5 min, then abruptly lowered to 50 Torr for 20 min, and finally returned to 100 Torr for the last 5 min. End-tidal PCO 2 (PET CO 2 ) was held at 1-2 Torr above its normal value throughout the experimental period. The hypoxic exposure was repeated three times for each subject under both pharmacological conditions, at 1, 2, and 4.5 h after placebo/haloperidol administration. Ten minutes before each exposure, a venous blood sample (10 ml) was taken for measurement of haloperidol concentration as described below.
An anticholinergic drug (procyclidine, single dose of 5 mg po) was available to reverse the side effects of haloperidol, either during the course of an experiment, in which case the experiment was abandoned, or after the experiment if the subject felt uncomfortable.
To assess the level of side effects, we used a brief questionnaire that was sent to the subjects a few days after the experiment.
Measurement of plasma haloperidol concentrations. The plasma samples were analyzed by Cozart Bioscience (Abingdon, Oxon, UK). A haloperidol microplate enzyme immunoassay, which is a solid-phase immunoassay designed to work with a sample of urine, serum, and whole blood, was used. The test was performed in microwells coated with a highaffinity antibody. A sample was added to the wells followed by an enzyme conjugate. During the following incubation period, the enzyme conjugate competed with the drug in the sample for binding sites on the antibody-coated well. After a wash step to remove any unbound material, substrate was added for the final color-development process. The color intensity is inversely proportional to the amount of drug present in the 0161-7567/97 $5.00 Copyright 1997 the American Physiological Society sample. Therefore, those samples that contain the drug would inhibit the binding of the enzyme conjugate to the capture antibody, resulting in less color than in the negative control. Haloperidol concentration in the samples was then obtained by reading the absorbance of the wells with a microplate reader and comparing the color intensity with known controls. The minimum level of detection of the assay was 0.4 mg/ml. Control samples were run with the assay, with a maximum variation of Ϯ10% being taken as acceptable.
Respiratory measurements. Subjects were seated comfortably and breathed through a mouthpiece with the nose occluded. A pulse oximeter was attached to a finger to monitor oxygen saturation, and electrodes were placed on the chest to obtain the electrocardiogram. The mouthpiece was connected in series with a turbine volume-measuring device (10) and a pneumotachograph to measure respiratory volumes and flows. Gas was sampled at the mouth continuously and analyzed for PCO 2 and PO 2 by mass spectrometry. All experimental data were recorded in real time at a sampling frequency of 50 Hz by computer, which also determined PET O 2 and PET CO 2 together with the inspiratory and expiratory volumes and durations. The end-tidal gas values were then passed, breath by breath, to a second computer, which controlled a fastresponding gas-mixing system. The computer that controlled the gas-mixing system compared the actual end-tidal values with the desired values and, to obtain the desired end-tidal profile, made appropriate adjustments to the inspired gas. The details of the forcing procedure and the gas-mixing system are described in greater detail elsewhere (10, 18) .
Data analysis. The experiment resulted in three sets of data for each subject in each pharmacological condition. Data from each trial were time averaged over 60-s intervals. From these, four 1-min periods were used to calculate the magnitude of the rapid component of the ventilatory responses at the onset (on-response) and relief (off-response) of hypoxia and the magnitude of HVD. The four periods ( Fig. 1) were 1) the last minute of the first euoxic period (prehypoxic ventilation), 2) the second minute of the hypoxic period (peak ventilation), 3) the last minute of the hypoxic period (depressed ventilation), and 4) the second minute of the euoxic recovery period (posthypoxic ventilation). The on-response was calculated as the difference between peak and prehypoxic ventilation. The magnitude of HVD was obtained as the difference between peak and depressed ventilation. The magnitude of the off-response was calculated as the difference between depressed and posthypoxic ventilation.
Statistical differences between the various measures of the ventilatory response to the end-tidal gas profile in the two conditions were assessed by using analysis of variance (ANOVA) with subjects as a random factor and drug (placebo or haloperidol) and time (1, 2, 4.5 h) as fixed factors, together with the interactive terms. A probability of Ͻ0.05 was taken as statistically significant. Analysis was undertaken by using the SPSS statistical software package.
RESULTS
Side effects of haloperidol. Ten of the 15 subjects that took part reported side effects from the administration of haloperidol. Three did not wish to finish the study and were treated with procyclidine before completion. These three subjects reported unpleasant agitation, uncomfortable restlessness, a feeling of tenseness, and an inability to sit still (akathisia). Their data are not included in the results. The other seven who felt side effects reported agitation, restlessness, and akathisia to varying degrees but always only beginning 2 h or more after drug administration. No subject felt side effects from the placebo.
Measured concentrations of drug. The haloperidol concentrations for the three blood samples (1, 2, and 4.5 h after drug administration) from each subject are Table 2 . The concentration increased over time, consistent with reported times to peak plasma concentration of 1.7-3.2 h (9) and 4.5 h (12), although the pharmacokinetics for haloperidol are known to show wide intersubject variation. This increase in concentration is consistent with the intensification of side effects observed over time.
Quality of gas control. The quality of the gas control obtained is illustrated for one subject on a breath-bybreath basis in Fig. 2 . Averages for individual subjects are shown in Fig. 3 . PET CO 2 values were held constant throughout most of the exposure but did vary slightly in a few subjects during transitions into and out of hypoxia. PET O 2 was lowered and raised abruptly at the onset and relief of hypoxia.
Ventilatory responses. Figure 3 and Table 3 show the ventilatory responses for each individual subject (average of 3 repeats for each protocol). The general form of response to the hypoxic exposure seems similar in all subjects. Of particular note is that haloperidol does not appear to have suppressed HVD (it increased HVD in 7 subjects and reduced it in 5 subjects). However, both the on-response (all subjects) and the off-response (all but 2 subjects) appear greater after administration of haloperidol than during control conditions. The overall means for all subjects in each pharmacological condition are illustrated in Fig. 4 and appear consistent with the above observations.
In view of the rising concentration of haloperidol over the repeats of the protocol at 1, 2, and 4.5 h, it is possible that taking the mean of the three repeats is obscuring a dose-dependent effect. This possibility is examined in Fig. 5 , where the ventilatory responses have been averaged across all subjects but where the three averages for the repeats have been kept separate. No differential effects over time are apparent from Fig. 5 .
The above impressions were tested statistically by using ANOVA. There was no significant effect of time in either protocol. The on-response was significantly greater after pretreatment with haloperidol compared with the control condition (P Ͻ 0.001), as was the off-response (P Ͻ 0.001). There was, however, no significant difference (P ϭ not significant) in the magnitude of HVD between the two pharmacological conditions.
DISCUSSION
Effect of haloperidol on the AHVR to hypoxia.
Our results demonstrate that the ventilatory sensitivity to hypoxia is increased after pretreatment with haloperidol, a peripherally and centrally acting dopamine antagonist. This appears inconsistent with the results of Bainbridge and Heistad (1), who found that haloperidol, in a dose similar to that used in the present study, did not have any significant effect on the ventilatory response to hypoxia. One important difference between the two studies was that the exposures to hypoxia used by Bainbridge and Heistad were poikilocapnic rather than isocapnic, and this resulted in rather small increases in ventilation of only 1.4 l/min in control experiments and 1.7 l/min in experiments with haloperidol. This might have masked an effect of haloperidol on AHVR. Other differences between the two sets of experiments include the route of administration of the drug and the time at which the measurements were Other studies in humans that have used different dopamine antagonists, droperidol (22) and prochlorperazine (16) , have, as in the present study, found an augmented hypoxic ventilatory response. Both these antagonists, like haloperidol, cross the blood-brain barrier and are both centrally and peripherally acting. Mean Ϯ SE 13.7 Ϯ 1.2 5.9 Ϯ 0.8 9.3 Ϯ 1.6 17.9 Ϯ 1.9 9.5 Ϯ 1.3 9.9 Ϯ 2.1
Values are for 12 subjects given in l/min. For explanation of on-response, off-response, and hypoxic ventilatory depression or decline (HVD), see Fig. 1 . The effects of haloperidol on AHVR are very similar to those obtained with domperidone, a peripheral dopamine antagonist that does not cross the blood-brain barrier. In the present study the mean increase in AHVR with haloperidol was 31%. Bascom et al. (2) obtained an average increase in AHVR with domperidone of 39%. Foo et al. (8) found an increase in AHVR of 19.6% with domperidone. In the study by Bainbridge and Heistad (1), the actual change in AHVR with haloperidol was 21%; however, possibly because of the very low ventilatory responses to poikilocapnic hypoxia (1.4 and 1.7 l/min, respectively), the changes did not reach statistical significance. The similarity between the results for domperidone and those for haloperidol suggests that the effect of haloperidol on AHVR is mostly peripheral, with little central modification.
The effect of haloperidol on the AHVR was constant throughout the experiment, despite the fact that the concentration of haloperidol in the blood increased substantially between repeats of the hypoxic exposure. This suggests that the effect was already fully developed after 1 h at the very lowest concentration. This result is consistent with the finding that other peripheral effects of haloperidol can be obtained at low dose; in particular the antiemetic effect of haloperidol is obtained with a postoperative dose of 0.5-1.0 mg. Chow et al. (4) reported dose-response curves for haloperidol (0.1-1,000 µg/kg) in the anesthetized cat. They found that haloperidol produced a dose-related progressive increase in ventilation over the range of very low-dose haloperidol (0.1-10 µg/kg), an increased but steady response at low dose (10-100 µg/kg), and a tendency for depression of ventilation at any higher dose. These findings are consistent with our finding that the full effect of haloperidol on AHVR is reached at very low dose. With use of a standard volume of distribution in the midrange of estimates of 15 l/kg (9), our blood concentrations would correspond to intravenous doses of 1, 19, and 40 µg/kg at 1, 2, and 4.5 h. With the exception of the first measurement, these correlate well with the first part of the dose-response curve of Chow et al., where there is no further increase in ventilation with increasing dose of haloperidol.
Effect of haloperidol on HVD. Haloperidol at the dose used in this study did not have any significant effect on HVD in humans. We are unaware of any other results from human studies with which to compare this finding, but it appears to differ from the finding of Tatsumi et al. (21) that haloperidol abolished HVD in the cat. Two possible explanations for this difference are 1) a species difference and 2) a difference in the dose of haloperidol used. With respect to a species difference, one possibility is that HVD in the cat is a poor model of HVD in humans. Indeed, early work in the cat suggested that HVD occurred in the absence of a peripheral chemoreceptor input, whereas in humans the peripheral chemoreceptor input was required (17) . However, more recent work suggests that this difference may be related to anesthesia and that in awake cats a peripheral chemoreflex is required for HVD to occur (13, 17) . In the experiment of Tatsumi et al., the cats were studied awake as well as anesthetized, and an abolition of HVD was found in both cases.
Turning to the second possibility of a difference in dose of haloperidol, Tatsumi et al. administered a dose of haloperidol of 0.1 mg/kg iv to their cats. They found, in a preliminary study, that a dose of haloperidol of 0.3 mg/kg iv completely blocked the inhibitory effect of intravenous dopamine (10 mg) on carotid sinus nerve activity. They used the lower dose of 0.1 mg/kg in the main study to avoid the behavioral effects of the drug. However, even at this dose, they reported a transient hypoactivity and sedation that largely disappeared within 10 min. Similar hypoactivity and sedation in cats has been reported by Bonora and Gautier (3), who used a dose of 0.1 mg/kg iv. Bonora and Gautier also observed that this dose was sufficient to reverse the inhibitory effect of apomorphine, a centrally acting dopamine agonist.
In a pilot study we tried an oral dose of 0.1 mg/kg on three subjects to match the intravenous dose employed in the cat, but all subjects suffered intolerable side effects (akathisia, tenseness, etc.) after ϳ2 h. For this reason, for the study reported here, the postoperative dose was halved to 0.05 mg/kg. Even at this dose, side effects were seen in 10 of 15 subjects, with 3 subjects withdrawing from the study before completion. Thus our dose was chosen on the same criteria as used by In a comparison of the intravenous dose in the cats to the oral dose in humans, absorption is another factor that has to be considered. Bioavailability has been reported as in the range 60-65% (9) . The mean level of the drug at 4.5 h was 2.6 ng/ml. By using a standard volume of distribution of 15 l/kg (9) and assuming equilibration, this corresponds to a dose of 0.04 mg/kg, giving a bioavailability of 80%. These factors suggest that the majority of the drug was absorbed, and thus the route of administration is relatively unimportant.
In summary, both the cats used by Tatsumi et al. (21) and our human subjects exhibited some features associated with the central effects of haloperidol, and the difference between the actual doses employed is probably only a factor of about three. Hence, it seems unlikely that the different results between the two studies, in the one case complete abolition of HVD and in the other case no effect, can be attributed purely to differences in the dose of haloperidol employed.
Conclusion. We determined the following. 1) Combined peripheral and central dopamine-receptor antagonism in humans with haloperidol produces a similar pattern of change in the ventilatory response to sustained hypoxia to that seen with peripheral receptor antagonism with domperidone alone. 2) We have been unable to show in humans a decrease in HVD by the centrally acting drug as observed in cats.
